https://scholars.lib.ntu.edu.tw/handle/123456789/551103
標題: | Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection | 作者: | Yang W.-T. Wu L.-W TAI-CHUNG TSENG CHI-LING CHEN HUNG-CHIH YANG TUNG-HUNG SU Wang C.-C Kuo S.F.-T CHEN-HUA LIU PEI-JER CHEN DING-SHINN CHEN CHUN-JEN LIU JIA-HORNG KAO |
公開日期: | 2016 | 出版社: | Lippincott Williams and Wilkins | 卷: | 95 | 期: | 10 | 來源出版物: | Medicine (United States) | 摘要: | Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are 2 major causes of chronic viral hepatitis. It is still unclear how HCV coinfection affects HBV replication and clinical outcomes in HBV/HCV coinfected patients. We conducted a longitudinal study, which enrolled 111 patients with HBV/HCV coinfection and 111 propensity score-matched controls with HBV monoinfection. Both groups had comparable baseline age, sex, fibrosis stage, levels of HBV DNA, and HBV surface antigen (HBsAg). The HCV coinfection and other host/viral factors were correlated with various outcomes, including HBsAg loss and cirrhosis/hepatocellular carcinoma (HCC) development. After a 10-year follow-up, we found that HCV coinfection itself was not associated with HBsAg loss. However, coinfected patients with alanine aminotransferase (ALT) level >80 U/L had a higher chance of HBsAg loss than those with ALT level -80 U/L [hazard ratio (95% confidence interval): 4.41 (1.75-11.15)] or matched controls with HBV monoinfection [hazard ratio (95% confidence interval): 3.40 (1.54-7.50)]. Besides, both HCV coinfection and higher ALT levels were associated with higher HCC risks and the HCC risks remained even after HBsAg loss in HBV/HCV con-infected patient. HCV coinfection is not associated with HBsAg loss. A higher ALT level is a major determinant of HBsAg loss in patients with HBV/HCV coinfection. Both HCV coinfection and a higher ALT level were independent risk factors of HCC. Copyright ? 2016 Wolters Kluwer Health, Inc. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84962624443&doi=10.1097%2fMD.0000000000002995&partnerID=40&md5=e6750f46eab8f0d98138e02458151631 https://scholars.lib.ntu.edu.tw/handle/123456789/551103 |
ISSN: | 0025-7974 | DOI: | 10.1097/MD.0000000000002995 | SDG/關鍵字: | alanine aminotransferase; hepatitis B surface antigen; virus DNA; virus RNA; hepatitis B surface antigen; hepatitis C antigen; virus RNA; adult; alanine aminotransferase blood level; Article; cancer incidence; cancer prognosis; cancer risk; carcinogenesis; clinical feature; controlled study; female; follow up; hazard ratio; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis C virus; human; liver cell carcinoma; liver cirrhosis; major clinical study; male; middle aged; mixed infection; outcome assessment; priority journal; propensity score; viral clearance; virus load; virus replication; aged; Carcinoma, Hepatocellular; complication; forecasting; genetics; genotype; Hepacivirus; hepatitis B; hepatitis C; immunology; Liver Neoplasms; mixed infection; pathology; prognosis; retrospective study; risk factor; virology; young adult; Adult; Aged; Carcinoma, Hepatocellular; Coinfection; Female; Follow-Up Studies; Forecasting; Genotype; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Hepatitis C Antigens; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; RNA, Viral; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。